Acceder

Publicaciones - Metalofármacos antitumorales no convencionales

Cargando...
Alajarin M, Ballester FJ, Vivancos JA, Orenes RA, Vidal A, Sanchez-Andrada P, Marin-Luna M. Lewis Acid-Mediated Formation of 1,3-Disubstituted Spiro[cyclopropane-1,2'-indanes]: The Activating Effect of the Cyclopropane Walsh Orbital. J Org Chem. 2020 Mar 20;85(6):4565-4573. doi: 10.1021/acs.joc.0c00090. Epub 2020 Feb 27. PubMed PMID: 32077701.
AÑO: 2020; IF: 4.335
Ballester FJ, Ortega E, Bautista D, Santana MD, Ruiz J. Ru(ii) photosensitizers competent for hypoxic cancers via green light activation. Chem Commun (Camb). 2020 Sep 14;56(71):10301-10304. doi: 10.1039/d0cc02417a. Epub 2020 Aug 5. PubMed PMID: 32756717.
AÑO: 2020; IF: 5.996
Martínez-Carmona M, Ho QP, Morand J, García A, Ortega E, Erthal LCS, Ruiz-Hernandez E, Santana MD, Ruiz J, Vallet-Regí M, Gun'ko YK. Amino-Functionalized Mesoporous Silica Nanoparticle-Encapsulated Octahedral Organoruthenium Complex as an Efficient Platform for Combatting Cancer. Inorg Chem. 2020 Jul 20;59(14):10275-10284. doi: 10.1021/acs.inorgchem.0c01436. Epub 2020 Jul 6. PubMed PMID: 32628466; PubMed Central PMCID: PMC7116277.
AÑO: 2020; IF: 4.825
Ortega E, Zamora A, Basu U, Lippmann P, Rodríguez V, Janiak C, Ott I, Ruiz J. An Erlotinib gold(I) conjugate for combating triple-negative breast cancer. J Inorg Biochem. 2020 Feb;203:110910. doi: 10.1016/j.jinorgbio.2019.110910. Epub 2019 Oct 30. PubMed PMID: 31683128.
AÑO: 2020; IF: 3.212
Ballester FJ, Ortega E, Porto V, Kostrhunova H, Davila-Ferreira N, Bautista D, Brabec V, Domínguez F, Santana MD, Ruiz J. New half-sandwich ruthenium(ii) complexes as proteosynthesis inhibitors in cancer cells. Chem Commun (Camb). 2019 Jan 25;55(8):1140-1143. doi: 10.1039/c8cc09211g. Epub 2019 Jan 11. PubMed PMID: 30631876.
AÑO: 2019; IF: 5.996
Siguiente >

Instituto de Investigación Sanitaria Acreditado

ISCII

Metalofármacos antitumorales no convencionales